NEWS

Study highlights lower hospitalization rates in adults 65 years and older living in U.S. nursing homes who received an adjuvanted influenza vaccine versus standard trivalent influenza vaccine (TIV)

The Executive Order represents a significant step towards accelerating access to more effective technologies, such as cell-based platforms, immunity-enhancing adjuvants, and other innovative approaches.

New laboratory and office space will enhance influenza vaccine research and development and help the company prepare for Brexit.

This news release is intended for Health Professional media only.

This news release is intended for Health Professional media only.

Seqirus, a global leader in influenza prevention, today presented new scientific data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore that demonstrated circulating influenza B/Victoria (B/Vic) viruses are a closer match to cell-based B/Vic vaccine viruses compared with egg-based B/Vic vaccine viruses.

Seqirus announced it will feature data in 3 presentations and 24 posters on the company’s adjuvant and cell-based vaccines for seasonal and pandemic influenza at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore.

Seqirus, a global leader in influenza prevention, today opened its new Italian headquarters in San Martino, Monteriggioni, just outside Siena.

CSL Limited today named Anjana Narain, a seasoned leader in vaccines and biopharmaceuticals, as Executive Vice President and General Manager of its Seqirus business, one of the world’s largest influenza vaccines providers.

This news release is intended for business and trade media only.

This news release is intended for Health Professional media only.

This news release is intended for Health Professional media only.

The expansion will allow Seqirus to increase capacity for formulation, fill and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets.

Subject to final approval by the European Commission, Seqirus plans to launch the vaccine as FLUCELVAX® TETRA1 in Europe for the 2019/20 influenza season.

Human Vaccines Project and Seqirus Partner to Advance Universal Flu Vaccine Research

The project is intended to significantly improve access to antivenoms by combining a large antivenom donation, healthcare worker training, with a purpose-built distribution and product management system.

Seqirus partners with American Nurse Practitioner Foundation, American Pharmacists Association and Physician Assistant Foundation to drive conversation around flu prevention in adults 65 and older

This decision comes after Public Health England declared that conventional non-adjuvanted influenza vaccines provided little or no protection for adults aged 65 years and over in the 2016-17 flu season in the UK.